Skip to main content
Fig. 3 | Acta Neuropathologica Communications

Fig. 3

From: The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson’s disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain

Fig. 3

Rosiglitazone treatment protects retinal cells from rotenone-induced toxicity in rat primary mixed cell cultures and characterisation of a liposomal formulation of rosiglitazone. a AlamarBlue cell viability assays with mixed rat retinal cell cultures were used to determine the IC50 value of rotenone after 48 h exposure. b Rosiglitazone treatment, applied during the second half of the 48 h rotenone insult, conferred dose-dependent neuroprotection to mixed rat retinal cells. Results are representative of three repeated experiments. c 1 % Uranyl acetate stained TEM micrograph of rosiglitazone loaded liposomes. Scale Bar = 200 nm. d UV-absorbance spectra of rosiglitazone dissolved in DMSO demonstrating peak absorbance at 313 nm. e Plot of rosiglitazone concentration in DMSO against absorbance at 313 nm obeys Beer-Lambert’s law up to a concentration of 0.3 mM with a molar extinction coefficient of 4078 L.M-1.cm-1. f Incorporation efficiency of rosiglitazone containing liposomes was assessed spectroscopically before and after removal of unencorporated material by filtration. achieving a formulation incorporation efficiency of 40 % ± 6 % (n = 5)

Back to article page